GY-5

N/A

Report date: 2025/06/11 11:17:11

Base Information

Drug NameGY-5

Drug Alias Namerecombinant humanized anti-PD-1 monoclonal antibody (Shanxi Weiqida Guangming Pharmaceutical/Institute of Microbiology (CAS))PD-1 checkpoint inhibitor (Shanxi Weiqida Guangming Pharmaceutical/Institute of Microbiology, CAS)GY-5GY-14

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionProgrammed cell death protein 1 blockersT lymphocytes stimulantsImmunostimulants

TargetsProgrammed cell death protein 1

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesInstitute Of Microbiology Of Chinese Academy Of Sciences

China Registration ClassN/A

Develop Information

Active CompaniesShanxi Weiqidaguangming Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A